Stevens Capital Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Stevens Capital Management’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,586	Closed	-$33K	–	1089
2016 Q1	$33K	Buy	1,586 +305	+24%	+$7.52K	﹤0.01%	850
2015 Q4	$39K	Sell	1,281 -219	-15%	-$6.64K	﹤0.01%	890
2015 Q3	$37K	Sell	1,500 -124	-8%	-$3.7K	﹤0.01%	932
2015 Q2	$52K	Buy	+1,624	New	+$62K	﹤0.01%	971
2014 Q4	–	Sell	-2,694	Closed	-$52K	–	1186
2014 Q3	$52K	Buy	+2,694	New	+$76.1K	﹤0.01%	959

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stevens Capital Management's RIGL Position: Q2 2016 in Review

Stevens Capital Management sold out of Rigel Pharmaceuticals (RIGL) in Q2 2016, closing a stake of 1,586 shares — an estimated $33K sold.

Stevens Capital Management first reported a position in RIGL in Q3 2014 and held it in 5 quarters. The position peaked at $52K in Q2 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q2 2016.

Stevens Capital Management reported no remaining Rigel Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Stevens Capital Management sold 1,586 Rigel Pharmaceuticals shares in Q2 2016, an estimated $33K.
Stevens Capital Management first reported a position in Rigel Pharmaceuticals in Q3 2014 and held it in 5 quarters.
Stevens Capital Management's Rigel Pharmaceuticals position peaked at $52K in Q2 2015.
120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2016.

Based on Stevens Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.